A PHASE 1/2, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION STUDY OF TAK-280 IN
PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER
- Registry ID
- TAK-280-1501
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- TAKEDA DEVELOPMENT CENTER AMERICAS INC
- Start date
- 2024-04-17
- Completion date
- 2025-10-10
- Last update
- 2023-08-04
Conditions
Related clinical trials
- A PHASE 1/2, MULTICENTER, OPEN LABEL, DOSE ESCALATION & DOSE EXPANSION STUDY OF JK06, A 5T4 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
- IN VIVO LUNG PERFUSION (IVLP) AS AN ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE OR UNRESECTABLE PULMONARY METASTASES OF COLORECTAL CARCINOMAS
- A PHASE 1/2A TWO-PART, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF OC-001 AS MONOTHERAPY AND IN COMBINATION WITH AN ANTI-PD-L1 ANTIBODY IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS
- PHASE 1 STUDY OF ZW49 IN PATIENTS WITH LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC HER2-EXPRESSING CANCERS
- PHASE 1 TRIAL OF ZW25 IN PATIENTS WITH LOCALLY ADVANCED (UNRESECTABLE) AND/OR METASTATIC HER2-EXPRESSING CANCERS
View on source registry